The raised guidance and double-digit Royalty Receipts growth signal continued momentum in the core royalty portfolio. Watch for further R&D co-funding deals (J&J, Teva) and clinical catalysts (daraxonrasib pancreatic cancer data, Ziihera PDUFA date Aug 25, 2026) that could drive incremental upside to Portfolio Receipts.
RPRX drugs
RPRX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 6 $50.72entry
- T+1 · 6mo ago −1.03%α −0.69% · $50.20
- T+5 · 6mo ago +1.93%α +0.80% · $51.70
- T+20 · 6mo ago +8.38%α +5.60% · $54.97
- T+60 · 4mo ago +15.20%α +13.14% · $58.43
Price Chart
How similar events traded
Executive Summary
Royalty Pharma reported Q1 2026 Portfolio Receipts of $925M (+10% YoY) and Royalty Receipts of $887M (+13% YoY), driven by Tremfya, Voranigo, and Evrysdi. The company raised full-year 2026 Portfolio Receipts guidance to $3.325B-$3.450B (from $3.275B-$3.425B), reflecting expected Royalty Receipts growth of 4%-8%. Net cash from operations was $718M, up 20% YoY, and the company deployed $528M in capital during the quarter.
Key Financial Metrics
Key Facts
- Portfolio Receipts grew 10% YoY to $925M in Q1 2026
- Royalty Receipts grew 13% YoY to $887M
- Raised full-year 2026 Portfolio Receipts guidance to $3.325B-$3.450M (from $3.275B-$3.425B)
- Net cash from operations of $718M, up 20% YoY
- Adjusted EBITDA (non-GAAP) of $889M, up 21% YoY
- Portfolio Cash Flow (non-GAAP) of $722M, up 18% YoY
- Announced up to $1.25B in new royalty transactions in Q1
- Recorded $69M non-cash impairment charge related to Tazverik
- Repurchased 1.1M shares for $50M in Q1
Financial Impact
Portfolio Receipts guidance raised by $50M at midpoint; Royalty Receipts growth of 4-8% expected for FY2026
Risk Factors
- Promacta revenue declined 61% YoY due to generic competition
- Tazverik withdrawal and $69M impairment charge
- Potential for further generic erosion in the portfolio
- Interest expense increased to $94M from $65M YoY
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001802768-26-000008 |
| Document: 0001802768-26-000008-index.html | 0001802768-26-000008 |
| Document: 0001802768-26-000008.txt | 0001802768-26-000008 |
| 8-K Data (Synthetic) | 0001802768-26-000008 |
Track record
23 reports on RPRX
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +12.99% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry price pending
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $67.57 to $68.97 Now $68.53 +1.41% ▲ +2.07% −1.22% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $67.56 to $70.01 Now $68.53 +1.43% ▲ +3.63% +4.54% vs SPY
- Sep 30, 20266w ago Insider Cluster Bearish 5/10 Entry $57.63 to $56.21 Now $68.53 −18.91% ▲ +2.46% +3.77% vs SPY
- Sep 4, 202610w ago Press Release Bearish 5/10 Entry $60.59 to $58.47 Now $68.53 −13.10% ▲ +3.50% +2.38% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 3/10 Entry $60.57 to $61.92 Now $68.53 +13.14% ▲ +2.24% +1.12% vs SPY
- Aug 12, 202613w ago 144 Neutral 3/10 Entry $58.56 to $60.58 Now $68.53 +17.02% ▲ +3.45% +5.41% vs SPY
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $57.75 to $59.22 Now $68.53 +18.66% ▲ +2.55% +2.19% vs SPY
- Jul 2, 202619w ago Insider Cluster Neutral 2/10 Entry $57.77 to $57.96 Now $68.53 +18.62% ▲ +0.33% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers